The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine 1,2 . Drug combinations can help to fight multi-drug-resistant bacterial infections, yet they are largely unexplored and rarely used in clinics. Here we profile almost 3,000 dose-resolved combinations of antibiotics, human-targeted drugs and food additives in six strains from three Gram-negative pathogens-Escherichia coli, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa-to identify general principles for antibacterial drug combinations and understand their potential. Despite the phylogenetic relatedness of the three species, more than 70% of the drug-drug interactions that we detected are species-specific and 20% display strain specificity, revealing a large potential for narrow-spectrum therapies. Overall, antagonisms are more common than synergies and occur almost exclusively between drugs that target different cellular processes, whereas synergies are more conserved and are enriched in drugs that target the same process. We provide mechanistic insights into this dichotomy and further dissect the interactions of the food additive vanillin. Finally, we demonstrate that several synergies are effective against multi-drug-resistant clinical isolates in vitro and during infections of the larvae of the greater wax moth Galleria mellonella, with one reverting resistance to the last-resort antibiotic colistin.
. We used model laboratory strains rather than multi-drug-resistant (MDR) isolates to derive general principles behind drug-drug interactions without being confounded by horizontally transferred antibiotic resistance elements, and to facilitate follow-up experiments and comparisons with previous and future results. To further assess whether drug responses vary between strains of the same species, we included two strains per species (Extended Data Fig. 1a ), probing each in up to 79 compounds alone and in pairwise combinations. The compounds comprised 59% antibiotics (covering all major classes), 23% human-targeted drugs and food additives-most of which have reported antibacterial and/or adjuvant activity 4, 5 -and 18% other compounds with known bacterial targets or genotoxic effects, such as proton motive force inhibitors or oxidative damage agents, owing to their potential relevance for antibiotic activity and/or uptake 6, 7 (Extended Data Fig. 1a , Supplementary Table 1) . We profiled up to 2,883 pairwise drug combinations in each of the 6 strains (17,050 combinations in total). We assessed each drug combination in a 4 × 4 tailored-dose matrix (Methods, Supplementary Table 1), used optical density as growth readout and calculated fitness as the growth ratio between drug-treated and untreated cells (Extended Data Figs. 1, 2, Methods). All experiments were done at least twice, and on average four times, with high replicate correlation (average Pearson correlation = 0.93, Extended Data Fig. 3a, b) .
We quantified all drug-drug interactions using the Bliss independence model (Extended Data Fig. 1b , Methods). Consistent with its null hypothesis, interaction scores were zero-centred for all species (Extended Data Fig. 3c ). From all the scores (ε) obtained per combination (4 × 4 dose matrix), we derived a single interaction score (ε ) that ranged from −1 to 1 (Methods). Synergies and antagonisms were considered significant if P < 0.05 (Benjamini-Hochberg corrected, 10,000 repetitions of a two-sided Wilcoxon rank-sum test). Strong interactions had an additional effect size requirement for |ε | > 0.1, whereas weak interactions could satisfy the effect-size threshold for one of the two strains of the same species but be slightly below the threshold for the other (|ε | > 0.06, Methods). In total, we detected 19% interactions (synergies and antagonisms combined) for E. coli, 16% for S. Typhimurium and 11% for P. aeruginosa (Supplementary Table 2 ). These hit rates are between the >70% hit rate for 21 antibiotics previously tested in E. coli 8 and the <2% hit rate for a larger set of combinations previously tested in a number of different fungal species 9 . Discrepancies are likely due to: (i) drug selection biases, (ii) single-drug concentrations used in previous studies, which increase false-negative and -positive rates, and (iii) different strategies of data analysis. For example, we observed that drugs that lack antibacterial activity engage in fewer interactions (Extended Data Fig. 3e ): the previous study in fungi 9 screened pairwise combinations of 6 antifungals with 3,600 drugs, most of which had no antifungal activity-probably explaining the low number of interactions detected-and the study in E. coli 8 profiled only bioactive antibiotics. Out of the 79 drugs tested here, all had at least 1 interaction, and a median of 5-13 interactions, in the different strains (Extended Data Fig. 3f) .
Because, to our knowledge, drug combinations have not previously been systematically probed in bacteria, we lacked a ground truth for benchmarking our dataset. To overcome this limitation, we selected 242 combinations and created a validation set using higher-precision 8 × 8 checkerboard assays (Extended Data Fig. 4a , b, Supplementary Table 3, Methods). We used this validation set both to assess the performance of our interaction identification approach and to benchmark our screen (Extended Data Fig. 4c, d ). Overall, we had a precision and recall of 91% and 74%, respectively. The slightly lower recall can be partially explained by the larger coverage of drug concentration range in the validation experiments, which improves our ability to detect interactions (Extended Data Fig. 5 ). We confirmed 90% of all the weak interactions that we probed in the validation set (n = 46, Extended Data Fig. 6 , Supplementary Table 3) , which supports the rationale of our interaction identification approach. Indeed, including weak interactions in our Letter reSeArCH hits increases the recall (Extended Data Fig. 4d ). For a handful of the synergies observed between antibiotics of the same class (β-lactams), we confirmed the interactions using the Loewe additivity model (Extended Data Fig. 4e ), which is more suitable for assessing interactions between drugs with the same target.
Overall, we detected 1,354 antagonistic and 1,230 synergistic interactions. Although this suggests that the two occur with similar frequencies, antagonisms are nearly 50% more prevalent than synergies after correcting for our ability to detect both types of interactions (Fig. 1a) . This is because we can detect antagonisms only for 75% of combinations (when at least one drug inhibits growth; Extended Data Fig. 3d , Methods), whereas synergies are detectable for nearly all combinations. A higher prevalence of antagonisms has also been reported for antifungals 10 . Notably, antagonisms and synergies exhibited a clear dichotomy in our data. Antagonism occurred almost exclusively between drugs that target different cellular processes, whereas synergies were also abundant for drugs of the same class or that target the same process (Fig. 1b-e , Extended Data Fig. 7 ). Mechanistically, antagonism can be explained by interactions at the drug-target level, as the two inhibitors can help the cell to buffer the distinct processes that are perturbed. DNA and protein synthesis inhibitors act this way in bacteria 11 ( Fig. 1b) . Consistent with this being a broader phenomenon, in genome-wide genetic interactions studies in yeast, alleviating interactions (antagonisms) are enriched between essential genes (the targets of anti-infectives), which are part of different functional processes 12 . However, antagonism can also occur at the level of intracellular drug concentrations (Extended Data  Fig. 8a ). We tested 16 antagonistic interactions of different drugs with gentamicin or ciprofloxacin in E. coli to investigate the extent to which this occurs. Although initially detected at a growth inhibition level, all antagonisms held true at a killing level, with 14 of the 16 antagonisms working (at least partially) via decreasing the intracellular gentamicin or ciprofloxacin concentrations (Extended Data Fig. 8b ). In several of the cases that we tested, this probably occurred because the second drug decreased the proton motive force-energized uptake of gentamicin or increased the AcrAB-TolC-dependent efflux of ciprofloxacin, as antagonisms were neutralized in the respective mutant backgrounds (Extended Data Fig. 8c ). Overall, our results suggest that a large fraction of antagonisms is due to modulation of intracellular drug concentrations, rather than to direct interactions of the primary drug targets (Extended Data Fig. 8d, e) .
Unlike antagonistic interactions, synergies often occurred between drugs that target the same cellular process (Fig. 1b -e, Extended Data Fig. 7 ). In fact, synergies are significantly enriched within drugs of the same category across all three species (P < 10 −16 , Fisher's exact test), given that in our dataset there are about 15-fold-more possible drug combinations across drug categories than within them. Mechanistically, by targeting the same functional process at different steps, drug combinations could bypass the redundancies of this process and thus have a synergistic effect. For example, the many synergies that exist between different β-lactams are probably because of their different affinities to the numerous and often-redundant penicillin-binding proteins (Fig. 1b , Extended Data Figs. 4e, 7a, b).
As with antagonisms, synergies can also occur owing to modulation of intracellular drug concentrations. Consistent with a general permeabilization role of membrane-targeting compounds in many organisms 9, 13, 14 and with drug uptake being a major bottleneck for Gram-negative pathogens, one quarter of all the synergies that we detected contained at least one out of the eight membrane-targeting drugs used in our screen (two-sided Wilcoxon rank-sum test, P = 0.06). However, membrane-targeting compounds also account for about 18% of antagonisms, which suggests that perturbations in membrane integrity can also decrease intracellular drug concentrations. Consistently, benzalkonium decreases the intracellular concentration of both gentamicin and ciprofloxacin, probably by interfering with their import into the cell (Extended Data Fig. 8b, c) .
We next examined the conservation of drug-drug interactions. Interactions within species were highly conserved (Fig. 2a, Extended  Data Fig. 9a, b) , with conservation being 53-76% depending on the species (Fig. 2b) . Conservation is actually higher (68-87%, on average 80%) if we disregard non-comparable interactions for which the concentration range tested precluded us from detecting synergy or antagonism for both strains (Fig. 2b, Extended Data Fig. 3d ). The high conservation of Letter reSeArCH drug-drug interactions within species is consistent with the finding that these interactions are generally robust to simple genetic perturbations 15 . Despite the high degree of conservation within species, 13-32% of the interactions remained strain-specific, with the majority being neutral in the second strain. Very few drug combinations synergized for one strain and antagonized for the other (16 interactions), but such strain differences held in our validation set (Supplementary Table 2) .
Although conservation is relatively high within species, it is very low across species (Fig. 2c, Extended Data Fig. 9c ). The majority (70%) of interactions occurred in only one species and only 5% were conserved in all three species, despite their close phylogenetic relationship. Because conservation is much higher at the single-drug level across the three species-which share resistance or sensitivity to 73% of the drugs (Supplementary Table 1 , Methods)-this indicates that drug combinations can impart species specificity to the drug action. Such specificities can be beneficial for creating narrow-spectrum therapies with low collateral damage, by using synergies that are specific to pathogens and antagonisms that are specific to abundant commensals.
Moreover, we found that despite synergies being less prevalent (Fig. 1a) , they are significantly more conserved than antagonisms (Fig. 2d) . This is presumably because (i) synergies are enriched between drugs of the same category, and interactions within functional processes are conserved across evolution 16 ; (ii) membrane-targeting drugs have a general potentiation effect in Gram-negative bacteria; and (iii) antagonisms often depend on drug import or uptake (Extended Data Fig. 8 ), which are controlled by less-conserved envelope machineries.
Exploring the network of conserved drug-drug interactions across the three species (Extended Data Fig. 9d ) exposed several potential Achilles' heels of Gram-negative bacteria, such as the strong synergy of colistin with macrolides 17 , and revealed that known antibiotic classes often behave non-uniformly. For example, the well-known synergy between β-lactams and aminoglycosides is confined to the potent aminoglycosides used in our screen (amikacin and tobramycin) and β-lactams (piperacillin, aztreonam and cefotaxime) that specifically target the cell-division-related penicillin-binding proteins, consistent with previous reports 18 . To address whether pairwise drug interactions are driven by mode of action (that is, drug classes interacting in a purely synergistic or antagonistic manner with one another) 8 , we calculated a monochromaticity index for all drug category pairs, across all species (Methods). For highly monochromatic category pairs, the monochromaticity index approaches 1 and −1 for antagonism and synergy, respectively. The monochromaticity index is high overall, especially between well-defined antibiotic classes. Yet, a number of these classes-including β-lactams, tetracyclines and macrolides-have mixed antagonisms and synergies with other antibiotic classes (Extended Data Fig. 9e ). β-lactams have diverse affinities to their multiple penicillin-binding-protein targets (potentially explaining the mixed interactions with other classes) but the same does not apply to protein synthesis inhibitors, which have unique targets. In this case, non-uniform class behaviour may be due to different chemical properties of the class members, and thus different dependencies on uptake and efflux systems. Aggregating the monochromaticity index per drug category reinforced the view that broader categories exhibit less concordant interactions (Extended Data  Fig. 9f ). Besides membrane-targeting drugs, human-targeted drugs were the category that exhibited the most synergies, which suggests that many human-targeted drugs may act as adjuvants.
Because antibiotic classes interacted largely in a monochromatic fashion, clustering drugs according to their interactions recapitulated the class groupings (Extended Data Fig. 10 ). For example, cell-wall inhibitors grouped together, with further subdivisions being reflective of target specificity. However, exceptions-such as the macrolides, which splitwere also evident. Azithromycin, the only dibasic macrolide, separates from its class co-members and clusters with two other basic antibiotics, bleomycin and phleomycin. Compared with other macrolides, azithromycin interacts with and crosses the outer membrane of Gram-negative bacteria in a distinct manner 17, 19 and also has different binding kinetics with the peptide exit tunnel of the 50S ribosomal subunit 20 . For drugs with unknown or less-well-defined targets, clustering hinted at possible modes of action. Among them, we selected the flavouring compound vanillin, which clusters together with the structurally related acetylsalicylic acid (aspirin). Salicylate and aspirin induce the expression of the major efflux pump in enterobacteria, AcrAB-TolC, by binding and inactivating the transcriptional repressor MarR 21 ( Fig. 3a) . Consistent with a similar action, vanillin treatment increased levels of AcrA protein in E. coli, owing to marA overexpression (Fig. 3b, c) . Higher AcrA levels upon vanillin or aspirin treatment led to higher minimal inhibitory concentrations for chloramphenicol and ciprofloxacin (Fig. 3d, e) . As previously reported for salicylate 22 , vanillin exerts an additional minor effect on drug resistance in a MarR-and MarA-independent manner ( Fig. 3c-e) , presumably via the MarA homologue Rob.
To test whether detected interactions are relevant for resistant isolates, we selected seven strong and conserved synergies-comprising antibiotics, human-targeted drugs or food additives-and assessed their efficacy against six MDR E. coli and Klebsiella pneumoniae clinical isolates in total. All strains were recovered from patients with infections, and belong to successfully spread clonal lineages that contain extended spectrum β-lactamase resistance and various highly prevalent carbapenemases 23, 24 . One K. pneumoniae strain (929) is also resistant to the last-resort antibiotic, colistin, owing to a chromosomal mutation Table 4 ) that puts the strain in the category of extensively drug-resistant isolates. All drug pairs acted synergistically in most of the strains that we tested (Fig. 4a, Extended Data Fig. 11a) . We further tested colistin-clarithromycin and spectinomycin-vanillin with an established infection model for evaluating antibacterial activity, using the larvae of G. mellonella. Both combinations also acted synergistically in vivo by increasing the rates of G. mellonella survival during infection (Fig. 4b, Extended Data Fig. 11b ).
The strongest of these synergies is between colistin and different macrolides (Fig. 4, Extended Data Fig. 11 ). Although other polymyxins are known to help macrolides to cross the outer membrane of Gramnegative bacteria 17 , this particular synergy occurred at low colistin concentrations (<0.3 μg ml ) and was active even for the intrinsically colistin-resistant strain (K. pneumoniae 929, Fig. 4) , which implies that macrolides may also potentiate colistin via an as-yet-unknown mechanism. Similar resensitization of colistin-resistant pathogens to colistin by macrolides was recently reported for plasmid-borne colistin resistance 25 , indicating that this synergy is independent of the resistance mechanism. In addition to antibiotic pairs, combinations of humantargeted drugs or food additives with antibiotics were also effective against MDR isolates, even when the former lacked antibacterial activity on their own (Extended Data Fig. 11 ).
One such compound, vanillin, potentiated the activity of spectinomycin in E. coli MDR isolates. This was intriguing, because vanillin antagonizes many other drugs including other aminoglycosides (Supplementary Table 2 ). We confirmed that this interaction is specific to spectinomycin and vanillin, and not to other aminoglycosides or aspirin, and thus independent of the vanillin effect on AcrAB-TolC (Extended Data Fig. 12a-c) . We then probed a genome-wide E. coli gene knockout library 26 to identify mutations that abrogate the vanillin-spectinomycin interaction, but do not influence the interaction between vanillin and amikacin (another aminoglycoside). Supplementary Fig. 1 
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One of the top hits was mdfA, which encodes a transporter of the major facilitator superfamily that exports both charged and neutral compounds 27 (Extended Data Fig. 12c ). Consistent with MdfA modulating spectinomycin uptake, ΔmdfA (mdfA deletion mutant) cells were more resistant to spectinomycin and not responsive to vanillin (Extended Data Fig. 12d ), whereas cells overexpressing mdfA were more sensitive to spectinomycin (Extended Data Fig. 12d , e), as previously reported 28 , with vanillin further exacerbating this effect (Extended Data Fig. 12d ). Vanillin addition also increased the intracellular spectinomycin concentration in an mdfA-dependent manner (Extended Data Fig. 12f ). At this point, it is unclear how MdfA-which is known to export compounds out of the cell-facilitates spectinomycin import into the cell. However, the phylogenetic occurrence of mdfA is concordant with the species-specificity of this interaction, as we detected this synergy in E. coli and S. Typhimurium but not in P. aeruginosa and K. pneumoniae isolates, which lack mdfA. This synergy underlines the importance of exploring the role of food additives in combinatorial therapies 5 . In summary, we generated a comprehensive resource of pairwise drug combinations in Gram-negative bacteria, which illuminates key principles of drug-drug interactions and provides a framework for assessing their conservation across organisms or individuals (Supplementary Discussion). Such information can form the basis for similar screens in other microbes, studies investigating the underlying mechanism of pairwise drug combinations 11, 15, 29 and computational predictions of their outcomes 30, 31 . Some of the principles that we have identified probably go beyond anti-infectives and microbes 32 . For antibacterial drug therapies, our study shows that non-antibiotic drugs hold promise as adjuvants, offers a new path for narrow spectrum therapies and identifies effective synergies against MDR clinical isolates (Supplementary Discussion). Further experimentation is required to address whether such synergies have clinical relevance.
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MEthodS
No statistical methods were used to predetermine sample size. Strains, plasmids and drugs. For each of the three Gram-negative species profiled in this study, we used two common sequenced laboratory strains: E. coli K-12 BW25113 and O8 IAI1 (hereafter IAI1), S. Typhimurium LT2 and 14028s, and P. aeruginosa PAO1 and PA14. To validate selected synergies, we profiled 6 MDR clinical Enterobacteriaceae isolates recovered from specimens from human patients: E. coli 124, 1027 and 1334, and K. pneumoniae 718, 929 and 980 (see Supplementary Table 4 for details of antibiotic resistance determinants). For follow-up experiments, we used two closely related E. coli K-12 model strains, BW25113 and MG1655.
All mutants used in this study were made using the E. coli Keio knockout collection 26 , after confirming with PCR and retransducing the mutation to wild-type BW25113 with the P1 phage (Supplementary Table 5 ). The kanamycin resistance cassette was excised when necessary using the plasmid pCP20 33 . The plasmid used for mdfA overexpression was obtained from the mobile E. coli ORF library 34 . Drugs used in this study were purchased from Sigma Aldrich, except for metformin hydrochloride (TCI Chemicals), clindamycin and bleomycin (Applichem), CHIR-090 (MedChemtronica) and vanillin (Roth). Stocks were prepared according to the supplier's recommendations (preferably dissolved in water). Minimal inhibitory concentration calculation. We defined minimal inhibitory concentration (MIC) as the lowest concentration required to inhibit growth of a microorganism after 8 h of incubation in lysogeny broth (LB) at 37 °C with shaking (384-well plates, starting with an optical density at 595 nm (OD 595 nm ) of 0.01). MICs of all drugs were computed using a logistic fit of growth (OD 595 nm for 8 h) over twofold serial dilutions of the antibiotic concentrations for all strains used for the high-throughput screening and follow-up experiments. High-throughput screening of pairwise drug interactions. For all drug combination experiments, drugs were diluted in LB to the appropriate working concentrations in transparent 384-well plates (Greiner BioOne GmbH), with each well containing 30 μl in total. After the addition of drugs, cells were inoculated at initial OD 595 nm of about 0.01 from an overnight culture. The same inoculum was used for all strains. All liquid handling (drug addition and cell mixing) was done with a Biomek FX liquid handler (Beckman Coulter). Plates were sealed with breathable membranes (Breathe-Easy) and incubated at 37 °C in a humidity-saturated incubator (Cytomat 2, Thermo Scientific) with continuous shaking and without lids to avoid condensation. OD 595 nm was measured every 40 min for 12 h in a Filtermax F5 multimode plate reader (Molecular Devices).
A flowchart of the experimental and analytical pipeline is shown in Extended Data Experimental pipeline. The drug-drug interaction screen was performed using 4 × 4 checkerboards. Sixty-two drugs were arrayed in 384-well plates with the different concentrations in duplicates (array drugs). Each plate contained 12 randomly distributed wells without arrayed drug: 9 wells containing only the query drug, and 3 wells without any drug. One query drug at a single concentration was added to all wells of the 384-well plate, except for the 3 control wells. All drugs were queried once-or occasionally twice-per concentration. We used 78 drugs as query in E. coli and S. Typhimurium, and 76 in P. aeruginosa. In total, 79 query drugs were screened, out of which 75 were common to all three species (Supplementary Table 1 ). The 62 array drugs were a subset of the 79 query drugs. The same drug concentrations were used in both query and array drugs (Supplementary Table 1 ). Three drug concentrations (twofold dilution series) were selected based on the MIC curves, tailored to the strain and drug. We targeted for nearly full, moderate and mild or no growth inhibition, which on average corresponded to 50-100%, 25-50% and 0-25% of the MIC, respectively. The highest drug concentration and the lowest fitness obtained per single drug are listed in Supplementary Table 1 . For drugs that do not inhibit growth on their own, we selected concentrations according to sensitivity of other strains or species, or to their use in clinics or for research. E. coli and S. Typhimurium exhibited largely similar single-drug dose responses within species, thus the same drug concentrations were used for both strains of each species. For P. aeruginosa, MICs often differed by several fold and drug concentrations were therefore adjusted between the two strains (Supplementary Table 1) . Growth curve analysis. The Gompertz model was fitted to all growth curves (when growth was observed) by using the R package grofit version 1.1.1-1 for noise reduction. Quality of fit was assessed by Pearson correlation (r), which was >0.95 for approximately 95% of all growth curves. r < 0.95 was indicative of either non-sigmoidal-shaped growth curves-typical of some drugs such as fosfomycinor noisy data. Noisy data were removed from further analysis. Plate effects were corrected by fitting a polynomial to the median growth of each row and column. The background signal from LB was removed by subtracting the median curve of the non-growing wells from the same plate. These were wells in which either the single-or the double-drug treatments fully inhibited growth; each plate contained at least three such wells. Data were processed per strain and per batch to correct for systematic effects. Fitness estimation. We used a single time-point OD 595 nm measurement (growth) for assessing fitness. This corresponded to the transition to stationary phase for cells grown without perturbation, as this enables us to capture the effect of drugs on lagphase, growth rate or maximum growth. Thus, we used OD 595 nm at 8 h for E. coli BW25113 and both P. aeruginosa strains, at 7 h for the fast-growing E. coli IAI1 and S. Typhimurium 14028s, and at 9 h for the slower-growing S. Typhimurium LT2.
We used the Bliss model to assess interactions as it can accommodate drugs that have no effect alone, but which potentiate the activity of others (adjuvants) 36 . This feature is especially relevant here, because we probed intrinsically antibiotic-resistant microbes (P. aeruginosa and MDR clinical isolates), and human-targeted drugs or food additives that lack antibacterial activity. According to the Bliss independence model 37 and assuming that drug-drug interactions are rare, for most drug combinations the fitness of arrayed drugs (f a ) equals the fitness in the presence of both drugs (f aq ) divided by the fitness of the query drug alone (f q ): in which ε denotes the Bliss score, f denotes fitness, g denotes growth, subscript a denotes that the variable pertains to an arrayed drug, subscript q denotes that the variable pertains to a query drug and 0 denotes no drug. The fitness in the presence of both drugs (f aq ) was calculated by dividing the growth in the presence of both drugs (g aq ) by the median of the growth of drug-free wells from the same plate (g 0 ).
The fitness of the single query drugs (f q ) was obtained by dividing the top 5% growing wells across each batch by the median of the growth of drug-free wells of each plate (g 0 ). This metric is more robust to experimental errors than using only the 9 wells containing the query drug alone. Nevertheless, both estimators for f q yield very similar results (Pearson correlation, r = 0.98). Consistent with equation (2), the fitness of arrayed drugs (f a ) was estimated by the slope of the line of best fit between g aq and g q across all plates (query drugs) within a batch.
n r (number of arrayed drugs) for a given array drug m (a m ) across n query drugs (q n ) within a batch (Extended Data Fig. 2b ).
For array drugs with a Pearson correlation (r) between g aq and g q below 0.7, f a was estimated using only the query drugs that corresponded to the interquartile range of g aq /g q (minimum n = 18 query drugs, Extended Data Fig. 2b ). Wells for which r was still below 0.7, even after restricting the number of plates were removed from further analysis owing to high noise (~2%). For wells exhibiting no growth for >75% of the plates within a batch, f a was deemed to be zero. Bliss independence interaction scores. Bliss scores (ε) were calculated for each well, as described in equation (1) . At least 3 × 3 drug concentrations × 2 (duplicates) × 2 (query and array drugs) = 36, or 18 (drugs used only as query) scores were obtained per drug pair. Drug-drug interactions were inferred based on the Bliss independence model in three steps: (i) strong interactions based on complete ε distributions, (ii) strong interactions based on ε distributions restricted to relevant drug concentrations and (iii) weak and conserved interactions within species. Cross-species comparisons, drug-drug interaction networks and monochromaticity analyses shown in this study include all drug-drug interactions. Strong drug-drug interactions based on complete ε distributions. Strong drug-drug interactions were statistically assigned using a re-sampling approach. Ten thousand repetitions of a two-sided Wilcoxon rank-sum test (per drug pair and per strain) were performed, to sample a representative set of ε for a given strain. For every repetition, the ε distribution of a given combination was compared to an ε distribution of the same size randomly sampled from the complete ε set for a given strain. P values were calculated as follows:
in which N is the total number of repetitions (10,000) and P n is the P value of the Wilcoxon rank-sum test obtained for the nth repetition. Strong drug-drug interactions were assigned to drug pairs that simultaneously satisfied two criteria: (i) first or third quartile of the ε distribution below −0.1 or higher than 0.1 for synergies or antagonisms, respectively, and (ii) P < 0.05 (after correcting for multiple Letter reSeArCH testing, Benjamini-Hochberg). Only one-sided drug interactions were taken into account, thus the very few interactions that satisfied the criteria concurrently for synergy and antagonism were re-assigned as neutral (only n = 1 for ε > |0.1|). The highest absolute ε value between the first and third quartiles was used as single interaction score (ε ) to reflect the strength of the drug-drug interactions. Strong drug-drug interactions based on ε distributions restricted to relevant drug concentrations. Because drug interactions are dependent on concentration, the same statistical procedure was repeated after restricting the drug concentration ratios to those relevant for either synergy or antagonism. This constraint was added by excluding ε values that corresponded to concentration ratios in which the expected fitness (product of the fitness on single drugs, f x × f y ) was below 0.2 for synergy and above 0.8 for antagonism, which represent blind spots for the given interaction type (Extended Data Fig. 3d ). These interactions are described by their P value and ε obtained with restricted drug concentration ratios. Although most interactions were detected based on both full and restricted ε distributions, each of the different methods uniquely identified interactions (Extended Data Fig. 4c ). With the expected fitness cutoff of 0.2, we identified the highest number of strong interactions (1,950) with 90 uniquely identified interactions from full ε distributions and 379 from restricted ε distributions (see also 'Sensitivity analysis').
Restricting ε values based on expected fitness also enables defining whether synergy or antagonism is detectable for any given drug pair. No significant P value was found for drug pairs with less than five ε scores within the relevant expected fitness space, as their sample size is insufficient. Synergy and antagonism could not be detected for 1% and 25% of all drug combinations, respectively. Weak and conserved drug-drug interactions within species. For drug pairs with a strong drug-drug interaction in only one of the two strains per species, the criteria for assigning interactions for the second strain was relaxed to |ε second strain | > 0.06, provided that the interaction sign was the same. Interactions assigned with this approach are termed weak and conserved. Loewe additivity interaction scores. For combinations between β-lactams for which high-resolution 8 × 8 checkerboards with sufficient growth inhibition were available in the validation dataset, Loewe additivity 38 was used to confirm the interactions. Drug-drug interactions were inferred by the shape of the isoboles (lines of equal growth) in two-dimensional drug-concentration plots. Unless stated otherwise, all isoboles correspond to 50% growth inhibition (IC 50 ) and were obtained by fitting a logistic model, with lines representing isoboles and dots representing IC 50 interpolated concentrations. To interpolate IC 50 concentrations (or other percentages of growth inhibition), a logistic model was used to fit the growth for each concentration of the first drug across different concentrations of the second drug. The null hypothesis of this model is represented by the additivity line: a linear isobole connecting equal individual growth inhibition values for the two drugs. Sensitivity analysis. We confirmed the adequacy of the main statistical parameters used to assign interactions by performing a sensitivity analysis. Several expected fitness (f x × f y ) cutoffs were tested, while keeping the other parameters constant (Extended Data Fig. 4c ). The added value of restricting the ε distributions to relevant drug concentrations (based on expected fitness) was strongly supported by the proportion of strong drug-drug interactions that was found exclusively using this criterion (~19% with our selected cutoff). The selected cutoff (0.2; disregarding wells with f x × f y < 0.2 for synergies and with f x × f y > 0.8 for antagonisms) resulted in the largest number of total interactions assigned, and the highest precision (91%) and recall (74%) after benchmarking against the validation dataset (Extended Data Fig. 4c) .
The suitability of the thresholds applied to define strong (|ε | > 0.1) and weak (|ε | > 0.06) interactions was assessed by their effect on the true-and false-positive rates (Extended Data Fig. 4d) . A threshold of | ε | > 0.1 is beneficial, as it imposes a minimum strength to assign interactions. A value of 0.1 corresponds to ~3 times the median of the first and third quartiles across all ε distributions (Extended Data  Fig. 2c ). Lowering this threshold results in lower true-positive rate, because several drug pairs are reassigned as neutral owing to ambiguity in calling interactions (we do not allow interactions to be both a synergy and an antagonism). Increasing this threshold lowers the true-positive rate, because only very strong interactions will be assigned (Extended Data Fig. 4d ). Drug-drug interactions are highly conserved within species, which is evident from the high correlation for ε that is observed for all species (Fig. 2a, Extended Data Fig. 9a, b) . This motivated us to relax the interaction-strength threshold for the second strain if the interaction score |ε | was above 0.1 in the first strain, dubbing these interactions weak and conserved. By including weak and conserved interactions in our analysis, the true-positive rate was increased by 15%. Adding a threshold for weak interactions of |ε | > 0.06 (about two times the median of the first and third quartiles of all ε distributions) is key for maintaining a low false-positive rate (Extended Data Fig. 4d ). Benchmarking and clinical isolates checkerboard assays. Eight-by-eight checkerboard assays were performed to validate our screen (242 drug combinations in the benchmarking dataset, Supplementary Table 3) , and to test 7 selected synergies against 6 MDR clinical isolates (Fig. 4, Extended Data Fig. 11) . As in the screen, growth was assessed on the basis of OD 595 nm at the transition to stationary phase for the no-drug controls. The time points used in the screen were used again for the validation set, and 8 h was used for all E. coli and K. pneumoniae MDR isolates. Fitness was calculated by dividing OD 595 nm after single-or double-drug treatment by no-drug treatment for each individual checkerboard. Bliss scores (ε) were calculated as before, resulting in 49 ε values per drug pair. Drug combinations were analysed on the basis of ε distributions, after removing wells in which one of the drugs alone-and its subsequent combinations with the second drug-completely inhibited growth. Antagonism was assigned when the median of the ε distribution was above 0.1, or the third quartile was above 0.15. Similarly, synergies were assigned when the median of the ε distribution was below −0.1 or the first quartile was below −0.15. All experiments were done in biological duplicates, and interactions were considered effective when duplicates were consistent (as was the case for the vast majority of interactions). Assessing conservation of drug-drug interactions. Conservation of drug-drug interactions between strains of the same species was assessed by Pearson correlation of the interactions scores, ε . For potentially non-conserved drug-drug interactions, the expected fitness distributions of the two strains were taken into account. When the two distributions were significantly different according to a two-sided Wilcoxon rank-sum test (P < 0.05 after Benjamini-Hochberg correction for multiple testing), the drug pairs were deemed as non-comparable between the two strains.
To assess the cross-species conservation of drug-drug interactions, we took into account only drug pairs that were probed in all three species. Drug-drug interactions were defined as being detected within a species when detected in at least one of the two strains and when no change of interaction sign was observed for the other strain. Interactions were then compared across the three species. Cases in which an interaction between drugs changed from synergy to antagonism or vice versa across species (conflicting interactions; ~7% of all interactions, Supplementary Table 2) were excluded from the comparative 'across-species' Venn diagram (Fig. 2c) . In current analysis, a given drug-drug interaction may be conserved across species but not conserved within the species.
Conservation at the single-drug level was defined on the basis of shared resistance and sensitivity (Supplementary Table 1) . A strain was considered sensitive to a given drug if one of the drug concentrations resulted in at least 30% growth inhibition. Consistent with conservation of drug-drug interactions across species, single-drug responses are conserved across species when at least one strain of both species has the same sign (sensitive or resistant). as an in vivo model to assess efficacy of drug combinations. Larvae were purchased from UK Waxworms and TZ-Terraristik. Stock solutions of vanillin (in 20% DMSO), spectinomycin, colistin and clarithromycin (in 20% DMSO and 0.01% glacial acetic acid) were freshly prepared and diluted in PBS to the required concentration. Drugs and bacterial suspensions were administered by injection of 10-μl aliquots into the haemocoel through the final pair of prolegs (bacteria into the left proleg, and antibiotics into the right), using Hamilton precision syringes. Controls included both uninfected larvae, and infected and uninfected larvae that were injected with the solvent used for the drugs. Drug toxicity was pre-evaluated by injection of serial dilutions of either single drugs or drug combinations, and drugs were used at amounts that caused little or no toxicity. To identify an optimal inoculum, time-kill curves were generated by inoculating larvae with 10 μl of serially diluted bacterial suspensions (1 × 10 2 -1 × 10 7 CFUs). For final experiments, groups of ten larvae were injected per strain-drug combination, placed into
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Petri dishes and incubated at 37 °C. Larvae were infected with a sublethal dose of 1 × 10 6 and 1 × 10 4 CFUs for E. coli and K. pneumoniae isolates, respectively, and subsequently injected with indicated drugs, 1-h after infection. Survival of the larvae was monitored at the indicated time points by two observers independently. Each strain-drug combination was evaluated in four independent experiments. Cell viability assays and intracellular antibiotic concentration. Ciprofloxacin. Overnight cultures of E. coli BW25113 were diluted 1:1,000 into 50 ml LB and grown at 37 °C to OD 595 nm ~0.5. Paraquat (50 μg/ml), vanillin (150 μg/ml), benzalkonium (5 μg/ml), caffeine (200 μg/ml), doxycycline (0.5 μg/ml), rifampicin (5 μg/ml), trimethoprim (5 μg/ml) or curcumin (100 μg/ml) were added to the cultures and incubated at 37 °C for 30 min. Ciprofloxacin (2.5 μg/ml final concentration) was then added to the cultures and cultures were incubated at 37 °C for 1 h in the presence of both drugs. Cell viability was determined by counting CFUs after plating washed cell pellets onto LB agar Petri dishes and incubating for 16 h. Intracellular ciprofloxacin was quantified using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), as previously described 40, 41 . Non-washed cell pellets 42 were directly frozen and lysed with 350 μl of acetonitrile, followed by three freeze-thaw cycles (thawing was performed in an ultrasonic bath for 5 min). Cell debris was pelleted at 16,000g and the supernatant was filtered through a 0.22-μm syringe filter before injection. Chromatographic separation was performed on a Waters BEH C18 column (2.1 × 50 mm; 1.7 μm) at 40 °C, with a 2-min gradient with flow rate of 0.5 ml/min: (i) 0-0.5 min, 1% mobile phase B; (ii) 0.5-1.2 min, linear gradient from 1 to 95% mobile phase B; (iii) 1.2-1.6 min, 95% mobile phase B; and (iv) 1.6-1.7 min, return to initial conditions. Mobile phase A consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid in acetonitrile. Samples were kept at 4 °C until analysis. Sample injection volume was 5 μl. Detection of ciprofloxacin was performed on a Waters Q-Tof premier instrument with electrospray ionization in positive mode. The transition 332 > 314 was monitored, with cone voltage set at 8 and collision energy set at 20. Intracellular ciprofloxacin was normalized to CFUs at the time of ciprofloxacin addition.
Gentamicin. Intracellular gentamicin was quantified by measuring [
3 H]-gentamicin (1 mCi/ml; Hartmann Analytic), as previously described 7 . Overnight cultures of E. coli MG1655 (the parental strain of BW25113) were diluted 1:100 into 5 ml LB and grown to OD 595 nm ~ 0.1. [ 3 H]-Gentamicin was diluted in cold gentamicin to obtain a 5 mg/ml (0.1 mCi/ml) stock solution, which was then added to the culture at a final concentration of 5 μg/ml (0.1 μCi/ml) together with the second drug: berberine (200 μg/ml), erythromycin (15 μg/ml), metformin (13,000 μg/ml), procaine (6,000 μg/ml), loperamide (400 μg/ml), benzalkonium (5 μg/ml), rifampicin (5 μg/ml) or clindamycin (200 μg/ml). Cultures were then incubated at 37 °C on a rotary shaker. At 0, 0.5, 1, 1.5 and 2-h time-points, 500-μl aliquots were removed and applied to a 0.45-μm-pore-size HAWP membrane filter (Millipore) pretreated with 1 ml of unlabelled gentamicin (250 μg/ml). Filters were washed with 10 ml of 1.5% NaCl, placed into counting vials and dried for 30 min at 52 °C. Subsequently, 8 ml of liquid scintillation was then added to the dried filters and vials were incubated overnight at room temperature before being counted for 5 min. Gentamicin uptake efficiency is expressed as total accumulation of gentamicin (in ng) per 10 8 cells. Cell viability was determined by CFUs. Spectinomycin. Intracellular spectinomycin was quantified by measuring [ 3 H]-spectinomycin (1 μCi/mg; Hartmann Analytic). Overnight cultures of E. coli BW25113 were diluted 1:1,000 into 1 ml LB with and without vanillin (150 μg/ml) and grown to OD 595 nm ~ 0.5. Then, 50 μg/ml [ 3 H]-spectinomycin:spectinomycin 1:100 was added and the cultures were incubated for 1 h. Cultures were pelleted, washed twice with PBS with 50 μg/ml non-labelled spectinomycin, re-suspended in 1% SDS and incubated for 20 min at 85 °C. The lysate was mixed with 8 ml liquid scintillation (Perkin Elmer ULTIMA Gold) and counted for 1 min using a Perkin Elmer Tri-Carb 2800TR. Measured radioactivity was normalized to cell number as measured by OD 595 nm . RNA isolation, cDNA preparation and quantitative RT-PCR. Overnight cultures of E. coli BW25113 and the marR deletion mutant (ΔmarR) were diluted 1:2,000 into 20 ml LB and grown at 37 °C to OD 595 nm ~ 0.2. Aspirin or vanillin were added to the cultures to a final concentration of 500 and 150 μg/ml, respectively (DMSO was added in the control), followed by a 30-min incubation period at 37 °C with agitation. Cells were collected and RNA was extracted using the RNeasy Protect Bacteria Mini Kit (Qiagen). cDNA was prepared for RT-qPCR using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). Levels of marA expression were estimated by RT-qPCR using SYBR Green PCR master mix following the manufacturer's instructions (Thermo Fisher Scientific). Primer sequences for marA and recA were as previously described 29 . All experiments were conducted in at least three biological replicates, and relative expression levels were estimated as previously described 43 , using recA expression as reference. Immunoblot analysis for protein quantification. Overnight cultures of E. coli BW25113 and the marA deletion mutant (ΔmarA) were diluted 1:1,000 into 50 ml LB containing 500 μg/ml aspirin, 150 μg/ml vanillin or DMSO (solvent control), followed by growth with agitation at 37 °C to OD 595 nm ~ 0.5. Cells were washed in PBS containing corresponding drugs or DMSO, then resuspended to match OD 595 nm = 1. Cell pellets were resuspended in Laemmli buffer and heated to 95 °C for 3 min followed by immunoblot analysis with anti-AcrA polyclonal antiserum (gift from K. M. Pos) at 1:200,000 dilution. Primary antiserum was detected using anti-rabbit HRP (A0545 Sigma) at 1:5,000 dilution. Cell loading was controlled with the anti-RecA antibody (rabbit, ab63797 Abcam). For densitometry analysis, the pixel intensity of AcrA bands from cell-density-normalized samples was quantified using ImageJ. At least four different biological replicates were blotted. Each biological replicate was run and blotted twice (technical replicates). Relative AcrA levels per biological replicate correspond to the average intensities of the technical replicates. All blots can be found in Supplementary Fig. 1 . Screening the E. coli Keio knockout collection for identifying the mode of action of drug interactions. The E. coli Keio knockout collection 26 (two independent clones per mutant) was arrayed in 1,536-format on LB agar plates using a Rotor HDA (Singer Instruments) as previously described 29 . The growth of each mutant was estimated by colony opacity 44 after a 13-h incubation at 37 °C in the absence and presence of vanillin (200 μg/ml), spectinomycin (4 μg/ml) and their combination. All plates were imaged under controlled lighting conditions (spImager, S&P Robotics) using an 18-megapixel Canon Rebel T3i (Canon). Experiments were done in biological triplicates. The fitness of each mutant was calculated by dividing the growth in condition (vanillin, spectinomycin or both) by the growth in LB, after correcting for outer-frame plate effects 44 . Bliss scores were calculated according to equation (1) Table 1 ). Antibacterial agents are grouped by target, with the exception of antibiotic classes for which enough representatives were screened (>2) to form a separate category (β-lactams, macrolides, tetracyclines, fluoroquinolones and aminoglycosides). Classification of human-targeted drugs and food additives is not further refined, because for most of these the mode of action is unclear. A subset of 62 arrayed drugs was profiled against 79 drugs in all 6 strains (75 drugs were common to all strains and are depicted in the heat map). Strains are colour-coded according to species: yellow, E. coli; red, S. Typhimurium; green, P. aeruginosa. b, Quantification of drug-drug interactions. Growth was profiled by measuring optical density (OD 595 nm ) over time in the presence of no, one and both drugs. x and y correspond to particular concentrations of drugs X and Y. Interactions were defined according to Bliss independence. Significantly lower or higher fitness than the expectation (f x × f y ) indicates synergy or antagonism, respectively. Synergy and antagonism were assessed by growth in 4 × 4 checkerboards (Methods). As drug-drug interactions are rare, the slope of the line of best fit between g aq (growth with double drug) and g q (growth with query drug alone, which was deduced from the average of the top 5% growing wells across plates within a batch), across plates (n p ) of query drugs within a batch, corresponds to a proxy of the fitness of the arrayed drug alone, f a (see Methods). r denotes the Pearson correlation coefficient between g aq and g q across n p . Well A9 from E. coli BW25113, containing 3 μg ml −1 spectinomycin, is shown as an example of arrayed drugs with several interactions. Several query drugs deviated from the expected fitness (light grey points), and therefore only half of the plates corresponding to the interquartile range of g ag /g q were used to estimate f a . c, Density distributions of the first, second and third quartiles of Bliss-score (ε) distributions for E. coli. Q1, Q2 and Q3 denote the median of the first, second and third quartiles of ε distributions, respectively. n denotes the number of drug combinations used.
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Letter reSeArCH Pearson correlation coefficients between plates of the same batch that contain only arrayed drugs (for which LB was used instead of the second drug). n represents the total number of correlations. Full box plots contain Pearson correlation coefficients between double-drug replicate wells within the same plate, across all plates. n represents the number of wells used for correlation, n max = (62 drugs + 1 LB) × 3 concentrations = 189. Only wells with median growth above 0.1 were taken into account for this correlation analysis (see b). For all box plots the centre line, limits, whiskers and points correspond to the median, upper and lower quartiles, 1.5 × interquartile range and outliers, respectively. b, Wells with lower median growth have lower replicate correlation. The double-drug correlation coefficients used to generate the box plot from a are plotted as a function of the median growth of all wells across all plates for E. coli IAI1. Wells with overall lower growth (due to the strong inhibition of the arrayed drug) are less reproducible owing to a combination of the lower spread of growth values and the sigmoidal nature of the drug-dose response curves. c, Drug-drug interactions are rare. Density distributions of all Bliss scores (ε) obtained per strain. d, The ability to detect synergies and antagonisms depends on the effects of single-drug treatments. Bliss scores (ε) are plotted as function of expected fitness (f x × f y ) for all drug concentration ratios for all combinations in E. coli BW25113 (as an example). Box plots summarizing both variables are shown besides the axes (n = 99,907 Bliss scores; centre line, limits, whiskers and points correspond to the median, upper and lower quartiles, 1.5 × interquartile range and outliers, respectively). Blind spots for detecting antagonism and synergy are indicated; both of these are based on the expected fitness (see also Extended Data Fig. 4c, d) , and are therefore dependent on the growth of the strain with the single drugs. The number of drug combinations falling in the blind spot for antagonism is larger, owing to the number of drugs used in the screen that do not inhibit E. coli on their own. e, Scatter plot of the number of interactions per drug versus the minimum fitness of the drug alone (as obtained in the screen, Supplementary Table 1) . Strong and weak interactions are represented. n denotes the total number of interactions and r is the Pearson correlation coefficient. Strains are colourcoded as above. f, Density distributions of the number of interactions per drug for all strains.
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Extended Data Fig. 4 | Benchmarking and sensitivity analysis. a, The validation set is enriched in synergies and antagonisms to better assess true and false positives. Comparison of percentages of synergy and antagonism between the screen and validation set. Both strong and weak interactions (Fig. 2b) are accounted for in the screen tally. b, Number of benchmarked interactions per strain. c, d, Sensitivity analysis of the statistical thresholds for calling interactions. c, The total number of interactions as a function of the expected fitness (f x × f y ) cutoff was used to restrict the ε distributions to relevant drug concentrations. Strong drug-drug interactions are classified according to the ε distribution in which they were significant: complete distribution only (that is, all expected fitness wells), relevant wells only (that is, all wells with f x × f y > cutoff for synergies and all wells with f x × f y < (1 − cutoff) for antagonisms), or in both. Weak drug-drug interactions are independently assigned and represented in white. We selected an expected fitness cutoff of 0.2, as this cutoff resulted in the largest number of total interactions detected, with the highest precision and recall (91 and 74%, respectively) after benchmarking against the validation dataset. d, Receiver operating characteristic curve for the screen across different P value thresholds (10,000 repetitions of a two-sided permutation test of Wilcoxon rank-sum test after correction for multiple testing, see Methods) as a unique criterion for assigning interactions. The selected P value (0.05) for the screen threshold is indicated by a grey cross. Sensitivity to additional parameters for calling hits is shown: allowing interactions to be either antagonisms or synergies but not both (onesided); as well as strong and weak interaction thresholds. True-and falsepositive rates were estimated based on the validation dataset. Precision and recall for the final and best-performing set of parameters are shown: one-sided interactions, P < 0.05, f x × f y cutoff = 0.2 and |ε| > 0.1 for strong interactions, |ε| > 0.06 for weak interactions. TP, true positive; TN, true negative; FP, false positive; FN, false negative. n indicates the total number of benchmarked drug combinations (Supplementary Table 3 ). e, Synergies between β-lactams according to the Loewe additivity interaction model. The results of 8 × 8 checkerboards for 3 combinations between β-lactams in 4 strains are shown. The grey line in each plot represents the null hypothesis in the Loewe additivity model and the black line corresponds to the IC 50 isobole, which was estimated by fitting a logistic curve to the interpolated drug concentrations (coloured dots, Methods). Piperacillin did not reach 50% growth inhibition in E. coli, thus IC 20 and IC 40 isoboles were used for the amoxicillin + piperacillin combination in E. coli BW25113 and E. coli IAI1, respectively. Typhimurium as an example of a weak conserved drug-drug interaction. Top box, the results of the screen. Left, Bliss scores as a function of expected fitness for both strains. Right, a density distribution of the Bliss scores. n denotes the total number of Bliss scores, Q1 and Q3 indicate the Bliss score for quartiles 1 and 3, respectively. A strong synergy was detected only for ST14028 (Q1 < −0.1), and a weak conserved synergy was assigned afterwards to ST LT2 (Q1 < −0.06). Bottom box, the benchmarking results confirm that the interaction is synergistic in both strains. The colour intensity on checkerboard reflects fitness and black dots correspond to drug ratios in which the Bliss score is below −0.1. One of the most well-known and broadly used synergies is that of aminoglycosides and β-lactams 45 . Consistent with its use against P. aeruginosa in clinics, we detected multiple strong synergies between specific members of the two antibiotic classes in P. aeruginosa but fewer interactions in the other two species.
c, d, Drug-drug interactions across cellular processes. Representation as in a, b but grouping drug categories targeting the same general cellular process. e, Quantification of synergy and antagonism in the networks from a, b and the corresponding χ 2 -test P value. As in E. coli (Fig. 1 ), antagonism occurs more frequently than synergy and almost exclusively between drugs belonging to different categories in S. Typhimurium and P. aeruginosa. In P. aeruginosa, there are very few interactions occurring between drugs of the same category (within the group). ) and ciprofloxacin (yellow, 2.5 μg ml −1 ) identified in our screen for E. coli BW25113 also rescue the killing effect of the two bactericidal drugs in the same strain, or its parental MG1655 (top right and top left panels, respectively). With the exception of clindamycin (for gentamicin) and curcumin (for ciprofloxacin), all other antagonists decrease the intracellular concentration of their interacting drug (bottom panels). Gentamicin was detected by using radiolabelled compound, and ciprofloxacin with LC-MS/MS (Methods). The degree of rescue (top panels) in many cases follows the decrease in intracellular concentration (bottom panels), which implies that most of these interactions depend at least partially on modulating the intracellular concentration of the antagonized drug. c, Antagonisms are resolved in E. coli BW25113 mutants that lack key components that control the intracellular concentration of the antagonized drug. Aminoglycosides depend on proton motive forceenergized uptake, and thus on respiratory complexes 7, 46 ; ciprofloxacin is effluxed by AcrAB-TolC 29, 47 . For gentamicin, most interactions are resolved when respiration is defected, even the interaction with clindamycin (which does not modulate intracellular gentamicin concentration, see b); this presumably occurs because the mode of action and import of aminoglycosides are linked by a positive feedback loop 7, 48 . For ciprofloxacin, antagonisms with paraquat and caffeine are resolved in the ΔacrA mutant, which implies that both compounds induce the AcrAB-TolC pump (well-established for paraquat 49 ). By contrast, interactions with curcumin, benzalkonium and doxycycline remain largely intact in the ΔacrA mutant. The first interaction is expected, as curcumin does not modulate intracellular ciprofloxacin concentration (see b). In the other two cases, other component(s) besides AcrAB-TolC may be responsible for the altered ciprofloxacin import and/or export; for example, ciprofloxacin uses OmpF to enter the cell 50 . Ciprofloxacin and gentamicin concentrations were adjusted in all strains according to MIC (70% and 100% MIC for ciprofloxacin and gentamicin, respectively; all drug concentrations are listed in Supplementary Table 6 ). Bliss interaction scores (ε) were calculated as in the screen. Bar plots and error bars in b, c represent the average and s.d., respectively, across n independent biological replicates. d, Gentamicin and ciprofloxacin antagonism networks for E. coli BW. Nodes represent drugs coloured according to targeted cellular process (as in Extended Data Fig. 1a ). Full and dashed edges represent antagonistic drug-drug interactions for which intracellular antibiotic concentration was and was not measured, respectively. Drug interactions that result in decreased intracellular concentration of the antagonized drug are represented by black edges. e, Quantification of antagonistic drug-drug interactions from the networks in (d). The bars for fluoroquinolones and aminoglycosides account for an extrapolation of antagonistic interactions to all other members of the two classes, assuming that they behave in the same way as ciprofloxacin and gentamicin, respectively. Fig. 2a . r denotes the Pearson correlation and n denotes the total number interactions plotted. The lower correlation in P. aeruginosa is presumably due to fewer and weaker interactions. c, Drug interaction profiles are driven by phylogeny. Clustering of strains based on the Pearson correlation of their drug interaction profiles (taking into account all pairwise drug combinations; n = 2,759-2,883 depending on the species). Strains of the same species cluster together; the two enterobacterial species-E. coli and S. Typhimurium-behave more similarly to one another than either does to the phylogenetically moredistant P. aeruginosa. d, Conserved drug-drug interaction network. Nodes represent individual drugs grouped and coloured by targeted cellular process (as in Extended Data Fig. 1a) . Drug names are represented by three-letter codes (given in Supplementary Table 1 ). Dashed and full edges correspond to conserved interactions between two or three species, respectively. Many of the human-targeted drugs, such as loperamide, verapamil and procaine, exhibit a general potentiating effect that is similar to that of membrane-targeting drugs. This suggests that these drugs may also facilitate drug uptake or impair efflux, consistent with previous reports on the role of loperamide in E. coli and verapamil in Mycobacterium tuberculosis 4, 51 . e, Monochromaticity between all drug categories. The monochromaticity index (MI) reflects whether interactions between drugs of two categories are more synergistic (MI= −1) or antagonistic (MI = 1) than the background proportion of synergy and antagonism. The MI equals zero when interactions between two drug categories have the same proportion of synergy and antagonism as all interactions together (Methods). The MI was calculated using all interactions from the six strains for all category pairs that had at least two interactions. White cells in the heat map correspond to category pairs for which no (or an insufficient number of) interactions were observed. f, Human-targeted drugs, and LPS or proton motive force inhibitors, are strong and promiscuous adjuvants. Density distributions of the monochromaticity indices per drug category from e are shown. n denotes the number of drugs in each category and i the number of interactions in which they are involved. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Data analysis was performed in RStudio Version 1.0.136, using R version 2.15.1. Scripts deposited at https://github.com/ AnaRitaBrochado/DrugInteractionsPipeline. Iris (doi:10.1038/nmicrobiol.2017.14) was used to process images of the E. coli gene knockout collection.
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Data exclusions Replicates with inconsistent growth behavior in the screen and validation dataset were excluded from our analysis. For follow up experiments, data exclusion was minimized to cases in which clear outliers due to technical mistakes were spotted. For noisy experiments, we increased the number of replicates.
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